Fiche publication
Date publication
avril 2025
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Annakib S, Di Méglio E, Dibert-Bekoy Y, Chevallier T, Roubaud G, Fournel P, Guillot A, Borchiellini D, Pouessel D, Boughalem E, Delva R, Barthelemy P, Oudard S, Thibault C, Tosi D, Houédé N, Fiteni F
Lien Pubmed
Résumé
Immune checkpoint inhibitors (ICIs) improved survival in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Patient-reported symptoms in this context were poorly studied. The study aimed to compare symptom severity between patients and clinicians.
Mots clés
PRO‐CTCAE, adverse drug events, bladder cancer, immune checkpoint inhibitors, patient reported outcome, pembrolizumab
Référence
Cancer Med. 2025 04;14(8):e70896
